[LUM#10] Dear Migraines
Anne Ducros is a neurologist at Montpellier University Hospital. As a migraine specialist, she treats patients who often find current medications ineffective. A new antibody-based treatment does exist, but its launch in France has been delayed. The reason? Its exorbitant price.
15% of French people suffer from migraines. This neurological condition remains poorly understood due to its complexity, involving at least forty genes. For 1% of patients, it takes a severe chronic form. Headache attacks occurring more than fifteen days a month cause not only intense pain but also sensitivity to noise and light, nausea, and vomiting—symptoms that current medications do not always manage to relieve. A new treatment, however, could change the lives of these thousands of people.
An initial targeted treatment
A new class of medications specifically designed for migraine. A first. “Until now,” explains Anne Ducros, a neurologist at Montpellier University Hospital and university professor, “we only had non-specific treatments. We still treat migraine sufferers with antihypertensives, antiepileptics, or antidepressants even though they are neither hypertensive, nor epileptic, nor depressed. ” These treatments help reduce brain excitability and thus the risk of migraine, but they expose patients to frequent and severe side effects such as drowsiness, difficulty concentrating, fatigue, shortness of breath…
In recent years, research has nevertheless identified the role of a small protein called CGRP. “A small peptide released during attacks by a nerve called the trigeminal nerve, which causes blood vessels to dilate and triggers a cascade of events leading to pain,” explains Anne Ducros. Researchers then developed antibodies capable of targeting and blocking CGRP, thereby stopping the migraine.
To date, four antibodies targeting either CGRP or its receptor have successfully completed clinical trials in patients who have not responded to conventional treatments. “At least half of the patients have seen a 50% reduction in their attacks; some have virtually none left. And those who haven’t seen an improvement with one type of antibody could very well respond to another,” explains the neurologist.
No side effects
Most importantly, this treatment has no side effects, other than “a slight soreness at the injection site in some people.” Unlike current long-term treatments, which are taken daily in the form of oral tablets, these antibodies are administered to patients via a simple monthly injection.
Simplicity and the absence of side effects are two factors that significantly increase patient adherence to treatment, as Anne Ducros points out: “Studies show that after one year, 80% of patients with chronic migraines are still taking their medication, whereas with conventional preventive treatments, 80% stop.”
These results led to the approval of antibody treatments bythe European Medicines Agency and the U.S. Food and Drug Administration, its American counterpart. When submitted to French authorities, they did grant approval for the treatment of severe migraine, but “they considered that there was no improvement in the medical benefit provided, so they are requesting further studies to demonstrate superiority over current treatments.” This makes it impossible for the drug to be released in 2019… So when? No one knows .
A decision that the specialist, in light of the published studies, does not understand. “Some of my patients who do not respond to conventional treatments had high hopes. When I tell them they’ll have to wait a little longer, they see it as a real injustice.”
550 euros per injection
This injustice is all the more glaring given that the main obstacle to bringing this new drug to market is reportedly its price: 550 euros per injection in the U.S. and Switzerland. This high cost is partly due to the length of the manufacturing process. “It takes five years to set up a production facility for an antibody that can yield a stable, pure, and effective therapeutic product,” explains Anne Ducros.
Today, while French doctors can prescribe these treatments to their patients, the patients must travel to Switzerland to purchase them. “For six injections, they pay 3,200 euros, so it works for those who can afford it, but for everyone else… It’s truly a two-tier healthcare system,” notes the neurologist. Before concluding with a wish—not such a far-fetched one: “There’s probably room for innovation to produce antibodies more cheaply… For moderately profitable companies.”
UM podcasts are now available on your favorite platform (Spotify, Deezer, Apple Podcasts, Amazon Music, etc.).